Tamoxifen and Aromatase Inhibitors: Which One, For How Long, and the Antidepressant to Avoid

Surgery removes the tumour. Chemotherapy and radiotherapy deal with what surgery could not reach. And then, for most women with hormone-receptor-positive breast cancer, there is one tablet a day for the next five to ten years.

That tablet is the part that prevents the cancer coming back. It is also the part that is hardest to keep taking, because the side effects arrive daily and the benefit is invisible.

🎯 What these drugs are doing

Around seven or eight in ten breast cancers are hormone-receptor-positive, meaning the cancer cells carry receptors for estrogen and use it as a growth signal. Endocrine therapy removes that signal, and it does so in two completely different ways.

That second row is the one that decides most prescriptions, and it explains something that confuses people: a premenopausal woman given an aromatase inhibitor without ovarian suppression is taking a drug that cannot work for her, because her ovaries are still producing estrogen directly and these drugs do not touch ovarian production.

In postmenopausal women the aromatase inhibitors are modestly more effective than tamoxifen at preventing recurrence, which is why they are usually first choice there. The difference is real and not enormous, and tolerability often decides between them.

⏳ Why five years became ten

Five years was the standard for decades. Then the follow-up data got longer, and two things became clear.

First, the risk of recurrence in hormone-receptor-positive breast cancer extends twenty years or more after diagnosis — it does not concentrate in the first five. Second, continuing to ten years reduces recurrence further in women at higher risk, and the extra benefit persists after the tablets stop.

So the common patterns now look like this:

• 🔹 Five years, where risk is low and tolerance is poor
• 🔹 Ten years of tamoxifen, in women who remain premenopausal
• 🔹 Five years of tamoxifen then switch to an aromatase inhibitor, where menopause has arrived during treatment
• 🔹 Five years of an aromatase inhibitor, extended to seven to ten, in higher-risk postmenopausal disease

One useful thing to know while taking it: the protective effect continues for years after the course ends. Tamoxifen in particular keeps reducing recurrence for a decade beyond the last tablet, which is why finishing the course matters more than it feels like at year four.

🚨 The interaction that can undo the treatment

This is the most important practical thing on the page, and it is missed constantly — because the circumstances that cause it are so ordinary.

A related point: around one person in fourteen of European ancestry has naturally low activity of this enzyme, which is one reason tamoxifen response varies. Testing for it is done in some centres and is not yet routine everywhere.

Also worth checking at the pharmacy counter: tamoxifen raises the effect of warfarin, so anyone on it needs closer monitoring of clotting.

💊 Tamoxifen: what to expect and what to report

Nolvadex (Tamoxifen) at 20 mg once daily, taken at the same time each day, with or without food. Most of what follows settles over the first months.

• 🌡️ Hot flushes and night sweats — the commonest complaint, often worst in the first three months. See the management section below, and note the interaction above before anything is prescribed for them
• 💧 Vaginal discharge or dryness, and reduced libido
• 😠 Mood changes and fatigue
• 🦵 Leg cramps, mild joint aches — usually milder than on an aromatase inhibitor
• ⚖️ Some weight change, though less than is commonly attributed to it

One more: tamoxifen can cause harm in pregnancy, and it is not a contraceptive. Reliable non-hormonal contraception is needed throughout treatment and for a period afterwards.

🦴 Aromatase inhibitors: the joint pain, and what actually helps

Arimidex (Anastrozole 1 mg) and Femara (Letrozole 2.5 mg), once daily, in postmenopausal women.

Their burden is different from tamoxifen and it is dominated by one thing: joint and muscle pain and morning stiffness, affecting up to around half of women on them. It is the single commonest reason the course gets abandoned, and it is widely treated as something to put up with when it is not.

The pain is typically worst in the first months and often eases. Hands and wrists are common sites, and some women develop carpal tunnel symptoms or a trigger finger, both of which are treatable.

The rest of the profile: hot flushes, vaginal dryness that tends to be worse than on tamoxifen, reduced libido, fatigue, and a rise in cholesterol worth monitoring. And the trade-off in their favour, worth remembering on a bad day: no womb lining risk and no clot risk.

🦴 Bones, which need actively managing

Aromatase inhibitors accelerate bone loss, and the loss is faster than ordinary postmenopausal loss. This is predictable and manageable, and it is the part most often left until a fracture happens.

• 📊 A baseline bone density scan before or soon after starting, and repeat scans during treatment
• 🥛 Calcium around 1000 to 1200 mg daily, from food where possible, and vitamin D with the level checked
• 🏋️ Weight-bearing and resistance exercise — the same prescription that helps the joint pain, which makes it the highest-value habit on this page
• 💊 A bisphosphonate or denosumab where density is already low or falling. Worth noting these also appear to reduce recurrence in postmenopausal women, so the conversation is not only about bone
• 🚬 Not smoking, and modest alcohol

Tamoxifen is the opposite in postmenopausal women — it protects bone there. In premenopausal women it causes some bone loss, which is one of the few arguments against it in that group.

🌸 The menopausal symptoms, and what is allowed

These drugs produce menopausal symptoms deliberately, and the usual treatment for menopausal symptoms is off the table. That leaves a real problem which has real answers.

Systemic hormone replacement is not an option in hormone-receptor-positive breast cancer.

For hot flushes, the non-hormonal options work and are described in our guide to menopausal symptoms:

• ✅ Venlafaxine 37.5 to 75 mg — the standard choice on tamoxifen, because it does not block the enzyme
• ✅ Escitalopram or citalopram — also safe with tamoxifen
• ✅ Gabapentin 300 to 900 mg at night, particularly for night sweats
• ✅ Cognitive behavioural therapy, which has real evidence for flush interference and sleep
• ❌ Paroxetine and fluoxetine — avoid on tamoxifen, as above

💪 What actually keeps people on treatment

Since finishing the course is the outcome that matters, the practical side deserves its own section.

• ⏰ Same time every day, attached to an existing habit. Any time of day works for all of these — the common question about the best time to take letrozole has no clinical answer beyond consistency, though some women find an evening dose means the joint stiffness peaks during sleep
• 📱 A reminder, because this is a five to ten year habit and motivation fades long before the course does
• 💊 A missed dose — take it when you remember unless it is nearly time for the next, in which case skip it. Do not double up. One missed tablet does not matter; a pattern of them does
• 🗣️ Report side effects early rather than enduring them. Nearly everything above has an answer, and the team cannot offer it if they do not know
• 🔄 Ask about switching before stopping. Three aromatase inhibitors and tamoxifen exist, and intolerance of one says little about the others
• 📅 Expect the first three months to be the worst. Much of this settles, and knowing that in advance is the difference between a bad quarter and an abandoned course

Mood deserves a mention of its own. Low mood and anxiety are common during these years, from the diagnosis as much as the drug, and they are treatable — with the enzyme caution above kept in mind. See our guides to low drive and anxiety.

📞 When to seek help

Before accepting a new prescription:

• Anything for hot flushes, low mood or anxiety while on tamoxifen — say the word tamoxifen first, and ask whether it inhibits CYP2D6
• Warfarin, which interacts with tamoxifen
• Any herbal or over-the-counter product, since several affect the same enzyme

Worth an appointment:

• Joint pain limiting daily life on an aromatase inhibitor — ask about switching to a different one before anything else
• Thinking about stopping —> raise it rather than simply stopping, because there is almost always an alternative
• No bone density scan after starting an aromatase inhibitor
• Vaginal dryness or pain with sex not helped by moisturisers — ask your oncologist specifically about low-dose vaginal estrogen
• Vitamin D never checked
• Periods stopping during treatment, which changes which drug is appropriate
• Planning surgery or a long flight on tamoxifen
• Planning a pregnancy — this needs discussing well in advance, and treatment interruption is sometimes possible under specialist supervision

❓ Frequently asked questions

📑 Sources and editorial

• Oncology society guidelines on adjuvant endocrine therapy for hormone-receptor-positive breast cancer, including choice of agent by menopausal status and recommended duration
• Collaborative meta-analyses of tamoxifen and aromatase inhibitor trials, including relative efficacy in postmenopausal women and the carryover effect after treatment ends
• Trials of extended endocrine therapy beyond five years, and long-term follow-up data on recurrence risk persisting for twenty years in hormone-receptor-positive disease
• Studies of adherence and early discontinuation of adjuvant endocrine therapy and their association with recurrence and mortality
• Pharmacological and clinical literature on tamoxifen as a CYP2D6-dependent prodrug, on endoxifen formation, and on the avoidance of strong CYP2D6 inhibitors including paroxetine and fluoxetine
• Data on CYP2D6 poor metaboliser prevalence and its relationship to tamoxifen outcomes
• Prescribing information for tamoxifen, including endometrial effects and the requirement to investigate abnormal vaginal bleeding, venous thromboembolism risk, ocular effects, warfarin interaction and pregnancy precautions
• Prescribing information for anastrozole, letrozole and exemestane, including dosing and the requirement for postmenopausal status or ovarian suppression
• Literature on aromatase inhibitor associated musculoskeletal syndrome, including reported frequency, natural history and the effect of switching between agents
• Randomised trials of exercise interventions and of duloxetine for aromatase inhibitor associated joint pain, and data on vitamin D status
• Guidance on bone health during aromatase inhibitor therapy, including baseline and interval bone density assessment, calcium and vitamin D intake, and indications for bisphosphonate or denosumab therapy
• Guidance on management of menopausal symptoms in breast cancer survivors, including non-hormonal options for vasomotor symptoms and the position on low-dose vaginal estrogen for genitourinary symptoms
• Related reading: menopausal symptoms and non-hormonal options, reduced libido, low drive, anxiety
• Related products: Nolvadex (Tamoxifen), Arimidex (Anastrozole), Femara (Letrozole), Effexor (Venlafaxine), Lexapro (Escitalopram), cancer category
• RXshop Editorial Team — reviewed by Anita Sharma, MD, FACOG — Obstetrician-Gynecologist & Women Health